Advertisement
CRBU vs RXRX
Which Stock Would AI Choose? Caribou Biosciences (CRBU) vs. Recursion Pharmaceuticals (RXRX) Stock Comparison
Key Takeaways
- CRBU has outperformed RXRX year-to-date with a 44% gain compared to 10%, driven by clinical progress in its CAR-T (chimeric antigen receptor T-cell) therapies.
- CRBU's smaller market capitalization of $221 million offers higher growth potential versus RXRX's $1.95 billion, but with elevated volatility (beta of 2.46 vs. 1.01).
- Recent momentum favors CRBU, up over 30% from recent lows around $1.68, while RXRX shows volatility amid partnerships.
- Analyst price targets imply substantial upside for CRBU at $11.12, highlighting pipeline catalysts like CB-011.
- Both operate in biotech, but CRBU focuses on CRISPR (clustered regularly interspaced short palindromic repeats) editing, while RXRX leverages AI for discovery.
Introduction
Caribou Biosciences (CRBU) and Recursion Pharmaceuticals (RXRX) represent cutting-edge approaches in biotechnology: gene editing and AI-driven drug discovery. Traders and investors tracking innovative therapies amid sector volatility may find this comparison valuable. Both stocks have experienced significant price swings in recent market activity, influenced by clinical updates, partnerships, and broader biotech sentiment. This analysis examines their business models, performance, and positioning to highlight relative strengths for informed decision-making in a dynamic environment.
CRBU Overview and Recent Performance
Caribou Biosciences (CRBU) is a clinical-stage biopharmaceutical company pioneering CRISPR-based genome editing for allogeneic CAR-T cell therapies targeting cancers like multiple myeloma. Its lead candidate, CB-011, has shown encouraging efficacy in phase 1 trials across multiple dose levels. In recent quarters, CRBU reported a narrower-than-expected Q4 loss of $0.28 per share (EPS, earnings per share) and topped revenue estimates at $3.94 million. Stock performance has surged over 200% in the past year and 44% year-to-date, rebounding sharply from 52-week lows near $0.73 amid positive analyst notes on CB-011's potential peak sales exceeding $700 million by 2040. Elevated trading volume and a beta of 2.46 reflect heightened volatility tied to trial data and financing updates, boosting sentiment in recent weeks.
RXRX Overview and Recent Performance
Recursion Pharmaceuticals (RXRX) is a clinical-stage TechBio firm utilizing AI and machine learning to decode biology and accelerate drug discovery across therapeutic areas. Recent expansions, including deepened partnerships with Citeline for AI-powered clinical trial data, underscore its platform's evolution. The company trades at a $1.95 billion market cap with a lower beta of 1.01, indicating relative stability. Year-to-date gains stand at 10%, with 33% over the past year, though shares have fluctuated between $2.80 and recent highs near $3.90 in recent market activity. Sentiment reflects mixed reactions to Q4 results and partnerships, with volume spikes on news but pullbacks amid broader sector pressures.
Trending AI Robots
Tickeron's Trending AI Robots page curates 25 top-performing AI trading bots from a library of 351, selected for their suitability in current market conditions. These bots employ diverse strategies like swing trading, trend following, and multi-agent systems across stocks, ETFs, and crypto, trading thousands of tickers in sectors from semiconductors to energy. Performance stats include annualized returns of 15% to 168%, win rates from 54% to 88%, profit factors up to 11.7, and trade durations from 1 day to 55 days. Virtual agents incorporate risk management, enabling copy trading without minimum balances. Explore these bots to align with your strategy in volatile markets like biotech.
Head-to-Head Comparison
CRBU and RXRX both target biotech innovation but diverge in models: CRBU's targeted CRISPR editing yields off-the-shelf therapies, while RXRX's AI platform maps biological relationships for broader discovery. Growth drivers contrast clinical milestones for CRBU versus data partnerships for RXRX. Recent momentum tilts to CRBU with superior returns, though RXRX offers scale. Risks include trial setbacks for CRBU (higher beta) and execution in AI scaling for RXRX. Sector exposure is pure biotech, with CRBU enjoying stronger analyst sentiment and upside potential.
Tickeron AI Verdict
Tickeron's AI currently leans toward CRBU due to its consistent upward trend, robust year-to-date gains, and clinical catalysts like CB-011 progress, positioning it favorably against RXRX's steadier but lower-momentum profile. Observable factors such as relative performance and analyst targets suggest higher probability of near-term strength for CRBU, though volatility warrants caution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRBU is a Hold and RXRX is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRBU’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).
- CRBU’s FA Score: 1 green, 4 red.
- RXRX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRBU’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 3 bullish TA indicator(s).
- CRBU’s TA Score: 4 bullish, 6 bearish.
- RXRX’s TA Score: 3 bullish, 7 bearish.
Price Growth
CRBU (@Biotechnology) experienced а -16.93% price change this week, while RXRX (@Biotechnology) price change was -4.98% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.78%. For the same industry, the average monthly price growth was +90.18%, and the average quarterly price growth was +2050.65%.
Reported Earning Dates
CRBU is expected to report earnings on Aug 11, 2026.
RXRX is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Biotechnology (+0.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| CRBU | RXRX | CRBU / RXRX | |
| Capitalization | 158M | 1.67B | 9% |
| EBITDA | -116.43M | -478.66M | 24% |
| Gain YTD | 0.314 | -22.983 | -1% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 11.2M | 65.7M | 17% |
| Total Cash | 118M | 654M | 18% |
| Total Debt | 26.9M | 72.4M | 37% |
| CRBU | RXRX | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 74% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 72% | 3 days ago 82% |
| Momentum ODDS (%) | 3 days ago 90% | 3 days ago 84% |
| MACD ODDS (%) | 3 days ago 90% | 3 days ago 88% |
| TrendWeek ODDS (%) | 3 days ago 89% | 3 days ago 88% |
| TrendMonth ODDS (%) | 3 days ago 90% | 3 days ago 81% |
| Advances ODDS (%) | 14 days ago 80% | 3 days ago 83% |
| Declines ODDS (%) | 3 days ago 88% | 5 days ago 88% |
| BollingerBands ODDS (%) | 3 days ago 88% | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 82% | 3 days ago 86% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FMPTX | 35.66 | 0.44 | +1.25% |
| Fidelity Advisor Mid Cap Value M | |||
| ARDGX | 32.91 | 0.27 | +0.83% |
| Archer Dividend Growth | |||
| HIIDX | 15.85 | 0.10 | +0.63% |
| Harbor Diversified Intl All Cp Inv | |||
| FAASX | 33.12 | 0.14 | +0.42% |
| Fidelity Advisor Asset Manager 70% A | |||
| DCFGX | 28.47 | 0.01 | +0.04% |
| Dunham Focused Large Cap Growth C | |||
CRBU and
Correlation & Price change
A.I.dvisor indicates that over the last year, CRBU has been loosely correlated with EDIT. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if CRBU jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To CRBU | 1D Price Change % | ||
|---|---|---|---|---|
| CRBU | 100% | -3.92% | ||
| EDIT - CRBU | 64% Loosely correlated | +2.46% | ||
| CRSP - CRBU | 58% Loosely correlated | -0.86% | ||
| RXRX - CRBU | 56% Loosely correlated | N/A | ||
| SANA - CRBU | 54% Loosely correlated | -3.25% | ||
| BEAM - CRBU | 52% Loosely correlated | -1.29% | ||
More | ||||
RXRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with ABSI. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then ABSI could also see price increases.
| Ticker / NAME | Correlation To RXRX | 1D Price Change % | ||
|---|---|---|---|---|
| RXRX | 100% | N/A | ||
| ABSI - RXRX | 60% Loosely correlated | +4.45% | ||
| ABCL - RXRX | 59% Loosely correlated | -0.57% | ||
| CRSP - RXRX | 58% Loosely correlated | -0.86% | ||
| PRME - RXRX | 58% Loosely correlated | -1.60% | ||
| BEAM - RXRX | 56% Loosely correlated | -1.29% | ||
More | ||||